Chetan Bettegowda

Johns Hopkins University

Full Professor(heuristic)

Glioma Diagnosis and Treatment · Genetics

h-index69

i10-index247

Publications736

Citations32,851

Grants

34 total · 13 active

NIH #5R01FD007271-04

Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 09172019

Expiring Soon

Amount: $669K
Period: 2021-09-01 → 2026-08-31
PIs: 3
Est. capacity / PI: ~0 students

Awarded at UNIVERSITY OF FLORIDA

NIH #2UE5NS065729-16

Research Education Program for Residents and Fellows in Neurology

Active

Amount: $319K
Period: 2009-03-01 → 2030-06-30
PIs: 2
Est. capacity / PI: ~0 students

NIH #5U01CA230691-08

Multi-analyte Approach for Earlier Detection of Cancers in Non Plasma Biofluids

Active

Amount: $709K
Period: 2018-09-19 → 2028-08-31
PIs: 3
Est. capacity / PI: ~0 students

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0045

PageRank within Genetics co-authorship network

Explore collaboration map

Admission Signals

New paper: Sa1082 NEO-SQUAMOUS EPITHELIUM IS NOT ALWAYS “NORMAL”: METHYLATION OF VIM AND CCNA1 PREDICTS RECURRENCE AFTER INITIALLY SUCCESSFUL ERADICATION OF DYSPLASTIC BARRETT’S ESOPHAGUS (Gastrointestinal Endoscopy)2026-05-01
New NIH award: $844K — Multi-omic CSF Assay for the Diagnosis of Brain Cancers2024-07-01
New NIH award: $669K — Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy2023-07-01
New NIH award: $636K — Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy2023-07-01
New NIH award: $691K — Integrating circulating tumor DNA assay and protein-based MRI to accurately monitor glioma therapy2023-07-01
New NIH award: $1,049K — Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation2022-09-22
New NIH award: $997K — Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation2022-09-22
New NIH award: $1,028K — Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation2022-09-22
New NIH award: $781K — Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation2022-09-22
New NIH award: $669K — Phase IIA Trial of Dichloroacetate for Glioblastoma Multiforme, IND137007, 091720192021-09-01

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0001-9991-7123

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 165

Sa1082 NEO-SQUAMOUS EPITHELIUM IS NOT ALWAYS “NORMAL”: METHYLATION OF VIM AND CCNA1 PREDICTS RECURRENCE AFTER INITIALLY SUCCESSFUL ERADICATION OF DYSPLASTIC BARRETT’S ESOPHAGUS
Gastrointestinal Endoscopy · 2026-05-01
Sa1084 DIAGNOSTIC PERFORMANCE OF AN ANEUPLOIDY-BASED CLASSIFICATION OF BARRETT’S ESOPHAGUS TO IDENTIFY INDIVIDUALS WITH PREVALENT NEOPLASIA
Gastroenterology · 2026-05-01
Sa1082 NEO-SQUAMOUS EPITHELIUM IS NOT ALWAYS “NORMAL”: METHYLATION OF VIM AND CCNA1 PREDICTS RECURRENCE AFTER INITIALLY SUCCESSFUL ERADICATION OF DYSPLASTIC BARRETT’S ESOPHAGUS
Gastroenterology · 2026-05-01
Sa1084 DIAGNOSTIC PERFORMANCE OF AN ANEUPLOIDY-BASED CLASSIFICATION OF BARRETT’S ESOPHAGUS TO IDENTIFY INDIVIDUALS WITH PREVALENT NEOPLASIA
Gastrointestinal Endoscopy · 2026-05-01
Ivosidenib and Vorasidenib Decrease Intratumoral 2-Hydroxyglutarate and Total Choline Levels in Patients with Lower-Grade Glioma: An <i>In Vivo</i> MR Spectroscopy Study
Clinical Cancer Research · 2026-04-17
Clinician perspectives on the clinical utility of Belay Summit™ 2.0 cerebrospinal fluid test – A mixed methods study
The Journal of Liquid Biopsy · 2026-04-15
Lethal toxin–equipped effector cells for the potential treatment of cancer
Proceedings of the National Academy of Sciences · 2026-03-16
Data‐Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain
Advanced Science · 2026-01-07 · 1 citations
TRBC2-targeting antibody–drug conjugates for the treatment of T cell cancers
Nature Cancer · 2025-12-22 · 2 citations
Figure S5 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S1 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S8 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S10 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Supplementary Tables S1 and S2 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S6 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S9 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S3 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S4 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12
Figure S7 from The Origin of Highly Elevated Cell-Free DNA in Healthy Individuals and Patients with Pancreatic, Colorectal, Lung, or Ovarian Cancer
2025-12-12

Open author page on OpenAlex →